The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Sagar LonialDuring the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US, answered: Is transplantation still relevant? If yes, in which context?
Is transplantation still relevant? If yes, in what context?
In this presentation, Lonial describes results from the FORTE (NCT02203643) and IFM 2009 (NCT01191060) trials, which investigated the use of triplet combinations with and without transplant. He warns of the 'siren song' of early MRD negativity that may lead one to believe novel agents are just as good as transplant. Lonial highlights that the focus needs to be on sustained MRD negativity; rates of which were higher in the patients who received a transplant. He also highlights two reasons for the discrepancy seen among early MRD negativity and sustained MRD negativity between patients who received a transplant and those who did not.
Is transplantation still relevant? If yes, in which context? Sagar Lonial
Sagar Lonial's slides are available as a downloadable resource below.
Is transplantation still relevant? If yes, in what context?
Find below links to the other talks from the symposium:
'Does 'cure' have a different meaning in MM?' presented by Mohamad Mohty.
'Is the treatment of high-risk smoldering multiple myeloma (SMM) the way for achieving the cure?' presented by María-Victoria Mateos.
'Treating elderly and frail patients with MM: Cure versus disease control' presented by Vincent Rajkumar.
'Roundtable discussion' with María-Victoria Mateos, Mohamad Mohty, and Sagar Lonial.